
Syed Taha Iqbal
Examiner (ID: 5838, Phone: (571)270-5857 , Office: P/1736 )
| Most Active Art Unit | 1736 |
| Art Unit(s) | 1793, 1736 |
| Total Applications | 941 |
| Issued Applications | 713 |
| Pending Applications | 67 |
| Abandoned Applications | 178 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 17297864
[patent_doc_number] => 20210393703
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-12-23
[patent_title] => COMPOSITIONS COMPRISING BACTERIAL STRAINS
[patent_app_type] => utility
[patent_app_number] => 17/464909
[patent_app_country] => US
[patent_app_date] => 2021-09-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 13493
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17464909
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/464909 | COMPOSITIONS COMPRISING BACTERIAL STRAINS | Sep 1, 2021 | Abandoned |
Array
(
[id] => 17213165
[patent_doc_number] => 20210346501
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-11
[patent_title] => ANIMAL PROTEIN-FREE PHARMACEUTICAL COMPOSITIONS
[patent_app_type] => utility
[patent_app_number] => 17/384388
[patent_app_country] => US
[patent_app_date] => 2021-07-23
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37711
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 13
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17384388
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/384388 | Animal protein-free pharmaceutical compositions | Jul 22, 2021 | Issued |
Array
(
[id] => 17200134
[patent_doc_number] => 20210340229
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
[patent_app_type] => utility
[patent_app_number] => 17/376416
[patent_app_country] => US
[patent_app_date] => 2021-07-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54324
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -16
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17376416
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/376416 | Immuno-based botulinum toxin serotype A activity assays | Jul 14, 2021 | Issued |
Array
(
[id] => 17080596
[patent_doc_number] => 20210275602
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-09
[patent_title] => Therapeutic bacterial composition
[patent_app_type] => utility
[patent_app_number] => 17/324898
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35809
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 103
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324898
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/324898 | Therapeutic bacterial composition | May 18, 2021 | Issued |
Array
(
[id] => 17201363
[patent_doc_number] => 20210341458
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => Bacterial Biomarker
[patent_app_type] => utility
[patent_app_number] => 17/324899
[patent_app_country] => US
[patent_app_date] => 2021-05-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35816
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17324899
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/324899 | Bacterial biomarker | May 18, 2021 | Issued |
Array
(
[id] => 16822766
[patent_doc_number] => 20210138059
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-05-13
[patent_title] => GLYCOCONJUGATE VACCINES COMPRISING BASIC UNITS OF A MOLECULAR CONSTRUCT EXPRESSING BUILT-IN MULTIPLE EPITOPES FOR THE FORMULATION OF A BROAD-SPECTRUM VACCINE AGAINST INFECTIONS DUE TO ENTEROPATHOGENIC BACTERIA
[patent_app_type] => utility
[patent_app_number] => 17/157969
[patent_app_country] => US
[patent_app_date] => 2021-01-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10681
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -1
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17157969
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/157969 | Glycoconjugate vaccines comprising basic units of a molecular construct expressing built-in multiple epitopes for the formulation of a broad-spectrum vaccine against infections due to enteropathogenic bacteria | Jan 24, 2021 | Issued |
Array
(
[id] => 16885419
[patent_doc_number] => 20210171614
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS
[patent_app_type] => utility
[patent_app_number] => 17/124747
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 54306
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 18
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17124747
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/124747 | Immuno-based botulinum toxin serotype A activity assays | Dec 16, 2020 | Issued |
Array
(
[id] => 17889819
[patent_doc_number] => 11452766
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-27
[patent_title] => Treatment of panic disorder using botulinum toxin
[patent_app_type] => utility
[patent_app_number] => 17/084833
[patent_app_country] => US
[patent_app_date] => 2020-10-30
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 3
[patent_no_of_words] => 10352
[patent_no_of_claims] => 10
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 68
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17084833
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/084833 | Treatment of panic disorder using botulinum toxin | Oct 29, 2020 | Issued |
Array
(
[id] => 16620067
[patent_doc_number] => 20210038720
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => METHOD FOR STABILIZING A TOXIN
[patent_app_type] => utility
[patent_app_number] => 17/071239
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 38723
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071239
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071239 | Method for stabilizing a toxin | Oct 14, 2020 | Issued |
Array
(
[id] => 16620054
[patent_doc_number] => 20210038707
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => AIPA, OMPA, AND ASP14 IN VACCINE COMPOSITIONS AND DIAGNOSTIC TARGETS FOR ANAPLASMA PHAGOCYTOPHILUM INFECTION
[patent_app_type] => utility
[patent_app_number] => 17/071385
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30655
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -5
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17071385
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/071385 | AipA, OmpA, and Asp14 in vaccine compositions and diagnostic targets for | Oct 14, 2020 | Issued |
Array
(
[id] => 16596662
[patent_doc_number] => 20210023193
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-01-28
[patent_title] => STREPTOCOCCUS PNEUMONIAE CAPSULAR POLYSACCHARIDES AND CONJUGATES THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/060337
[patent_app_country] => US
[patent_app_date] => 2020-10-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 20341
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -119
[patent_words_short_claim] => 61
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17060337
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/060337 | None | Sep 30, 2020 | Issued |
Array
(
[id] => 17726595
[patent_doc_number] => 11382960
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-07-12
[patent_title] => High frequency application of botulinum toxin therapy
[patent_app_type] => utility
[patent_app_number] => 17/009082
[patent_app_country] => US
[patent_app_date] => 2020-09-01
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9816
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 133
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17009082
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/009082 | High frequency application of botulinum toxin therapy | Aug 31, 2020 | Issued |
Array
(
[id] => 16511617
[patent_doc_number] => 20200390874
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-17
[patent_title] => YEAST-BASED IMMUNOTHERAPY AND TYPE I INTERFERON SENSITIVITY
[patent_app_type] => utility
[patent_app_number] => 17/007908
[patent_app_country] => US
[patent_app_date] => 2020-08-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28737
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17007908
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/007908 | Yeast-based immunotherapy and type I interferon sensitivity | Aug 30, 2020 | Issued |
Array
(
[id] => 16504835
[patent_doc_number] => 20200384091
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-10
[patent_title] => METHOD OF TREATING DEPRESSION
[patent_app_type] => utility
[patent_app_number] => 17/001447
[patent_app_country] => US
[patent_app_date] => 2020-08-24
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 6038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17001447
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/001447 | METHOD OF TREATING DEPRESSION | Aug 23, 2020 | Abandoned |
Array
(
[id] => 17605185
[patent_doc_number] => 11333664
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-05-17
[patent_title] => Methods for improving uptake of
[patent_app_type] => utility
[patent_app_number] => 16/986102
[patent_app_country] => US
[patent_app_date] => 2020-08-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 12
[patent_figures_cnt] => 21
[patent_no_of_words] => 8646
[patent_no_of_claims] => 7
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 156
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16986102
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/986102 | Methods for improving uptake of | Aug 4, 2020 | Issued |
Array
(
[id] => 16399113
[patent_doc_number] => 20200339971
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-10-29
[patent_title] => METHODS FOR THE MANUFACTURE OF PROTEOLYTICALLY PROCESSED POLYPEPTIDES
[patent_app_type] => utility
[patent_app_number] => 16/928107
[patent_app_country] => US
[patent_app_date] => 2020-07-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19016
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16928107
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/928107 | Methods for the manufacture of proteolytically processed polypeptides | Jul 13, 2020 | Issued |
Array
(
[id] => 16541016
[patent_doc_number] => 20200407429
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-31
[patent_title] => ANTIBODIES TO S. AUREUS SURFACE DETERMINANTS
[patent_app_type] => utility
[patent_app_number] => 16/925129
[patent_app_country] => US
[patent_app_date] => 2020-07-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33460
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16925129
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/925129 | Antibodies to | Jul 8, 2020 | Issued |
Array
(
[id] => 16483977
[patent_doc_number] => 20200377578
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2020-12-03
[patent_title] => NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE
[patent_app_type] => utility
[patent_app_number] => 16/919576
[patent_app_country] => US
[patent_app_date] => 2020-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 28286
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16919576
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/919576 | NEUTRALISING ANTIBODIES TO THE MAJOR EXOTOXINS TCDA AND TCDB OF CLOSTRIDIUM DIFFICILE | Jul 1, 2020 | Abandoned |
Array
(
[id] => 17028577
[patent_doc_number] => 11090375
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-08-17
[patent_title] => Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
[patent_app_type] => utility
[patent_app_number] => 16/899738
[patent_app_country] => US
[patent_app_date] => 2020-06-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 16
[patent_figures_cnt] => 16
[patent_no_of_words] => 65512
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16899738
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/899738 | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | Jun 11, 2020 | Issued |
Array
(
[id] => 17874379
[patent_doc_number] => 11446372
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-09-20
[patent_title] => None
[patent_app_type] => utility
[patent_app_number] => 16/848793
[patent_app_country] => US
[patent_app_date] => 2020-04-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 6
[patent_figures_cnt] => 12
[patent_no_of_words] => 5796
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 64
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16848793
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/848793 | None | Apr 13, 2020 | Issued |